Phase Ia/Ib single-centre, randomised, placebo-controlled, double-blind, dose-escalation study trial of SPI 3608 in healthy volunteers

Trial Profile

Phase Ia/Ib single-centre, randomised, placebo-controlled, double-blind, dose-escalation study trial of SPI 3608 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2013

At a glance

  • Drugs SPI 3608 (Primary)
  • Indications Musculoskeletal pain
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Aug 2013 Positive top-line results published in a Sucampo Pharmaceuticals media release.
    • 07 Aug 2013 Status changed from recruiting to completed, according to a Sucampo Pharmaceuticals media release.
    • 14 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top